Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status:
Completed
Trial end date:
2020-06-03
Target enrollment:
Participant gender:
Summary
This was the first study to test Sym023 in humans. The primary purpose of this study was to
see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or
metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or
for which no standard therapy is available.